Comparison of the Digene HPV Genotyping LQ Test and the PANArray HPV Genotyping Chip for Detection of High-Risk or Probable High-Risk Human Papillomavirus Genotypes

Abstract

BackgroundWe evaluated the performance of two different array-based techniques, a bead-based multiplex genotyping method (LQ; digene HPV Genotyping LQ Test, QIAGEN, Germany) and a DNA chip-based method using peptide nucleic acid probes (PANArray; PANArray HPV Genotyping Chip, Panagene, Korea), for detection of human papillomavirus (HPV) and genotyping of high-risk (HR) or probable high-risk (PHR) HPVs in healthy patients who visited a health-promotion center.MethodsWe obtained 508 unselected, consecutive cervicovaginal swab specimens. All specimens were examined by using the PANArray and LQ tests. All HPV-positive samples were then analyzed by multiplex PCR and direct sequencing.ResultsThe LQ test detected 47 HPV-positive cases (9.3%) with HR or PHR genotypes and the PANArray test identified 36 cases (7.1%). When the results of LQ and PANArray were compared by using comprehensive genotyping (integrated interpretation of the results of LQ, PANArray, multiplex PCR, and direct sequencing) for the detection of HR or PHR genotypes, the kappa values were 0.44 and 0.30 for LQ and PANArray, respectively. In comparison to comprehensive genotyping, the LQ test yielded 53 (60.0%) concordant and 12 (13.5%) compatible results, and the PANArray yielded 36 (40.4%) concordant and three (3.4%) compatible results.ConclusionsThe results of the LQ test had higher concordance and/or greater compatibility with those of comprehensive genotyping for the detection of HR or PHR genotypes than those of the PANArray test.

Comparison of Analytical and Clinical Performance of HPV 9G DNA Chip, PANArray HPV Genotyping Chip, and Hybrid-Capture II Assay in Cervicovaginal Swabs

“…There have been conflicting results about the PCR-based DNA chip method in previous studies in Korea. The majority of these studies reported that the HPV DNA chip method had higher or similar sensitivity or detection rates, compared to HC2 or other DNA tests [ 21 - 24 ], whereas some reports showed that commercial DNA chips had lower sensitivity or detection rates for HR-HPV [ 25 , 26 ]. Specifically, there were contradictory reports about comparative results of the PANArray method in the respective studies [ 24 , 26 ].…”

Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis

“…We adopted the findings reported in the meta-analyses for the sensitivity and specificity of cytology and HPV testing (Additional file 1: Table S4) [19,[57][58][59][60][61].…”

RNA and DNA Diagnostics

“…In one report regarding human papillomavirus (HPV) detection, a microspherebased multiplex genotyping method (digene HPV Genotyping LQ Test, QIAGEN, Germany) showed higher concordance than the results of using PNA-based methods (PANArray HPV Genotyping Chip, Panagene, Korea) with a pool of 508 clinical specimens (Park et al 2014). This report also verified that the microsphere-based genotyping method is superior to sequencing when determining multiple HPV genotypes existing in one subject, since low concentrations of DNA may lead to less sequencing accuracy (Park et al 2014).…”

“…In one report regarding human papillomavirus (HPV) detection, a microspherebased multiplex genotyping method (digene HPV Genotyping LQ Test, QIAGEN, Germany) showed higher concordance than the results of using PNA-based methods (PANArray HPV Genotyping Chip, Panagene, Korea) with a pool of 508 clinical specimens (Park et al 2014). This report also verified that the microsphere-based genotyping method is superior to sequencing when determining multiple HPV genotypes existing in one subject, since low concentrations of DNA may lead to less sequencing accuracy (Park et al 2014). In another study, Luminex Mebgen HPV assay was considered superior compared with other commercially available HPV tests such as Hybrid Capture ™ 2 (HC2) test from Qiagen, the Linear Array ™ HPV genotyping test/line-blot assay and the Amplicor ™ HPV test from Roche (Ozaki et al 2014).…”